A new low molecular weight heparan sulphate antagonizes kappa-carrageenan-induced thrombosis in rats.
Kappa-carrageenan (kappa-carrageenin; kappa-carragheen) was found to be thrombogenic in rats. After i.p. injection of 3 mg/kg of kappa-carrageenan the thrombosis extended to a maximum 7.5 cm from the tip of the tail. Infarction frequency as well as the extent of infarction were inhibited by oral administration of a new heparan sulphate of low molecular weight (LMW-HS) (alpha-idosane). Mesoglycan and heparin were active when administered by parenteral route, and aspirin showed no effect; mesoglycan was inactive at 50 mg/kg per os. The present data confirm the validity of this experimental model for evaluating the protective effects of antithrombotic drugs and show the activity of oral administration of a new drug endowed with fibrinolytic activity.
Gervasi
G B
GB
Laboratori-Baldacci S.p.A., Pisa, Italy.
Bartoli
C
C
Carpita
G
G
D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D002351:Carrageenan / Q000037:antagonists & inhibitors*; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006025:Glycosaminoglycans / Q000494:pharmacology; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology*; D007238:Infarction / Q000517:prevention & control; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012039:Regional Blood Flow / Q000187:drug effects; D013623:Tail / Q000098:blood supply; D013927:Thrombosis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*
D005343:Fibrinolytic Agents; D006025:Glycosaminoglycans; D006495:Heparin, Low-Molecular-Weight; C040617:mesoglycan; D002351:Carrageenan; D001241:Aspirin